ADITXT TO PRESENT bitXbio™ PLATFORM AT THE MONEYSHOW, FEB. 23–25

Presentation to highlight projects in autoimmunity, cancer, infectious diseases, and women’s health, with goals for 2026

MOUNTAIN VIEW, Calif., Feb. 19, 2026 — Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”) today announced that members of its leadership team will present at The MoneyShow, taking place February 23–25, 2026 in Las Vegas, NV, where the Company will introduce bitXbio, a platform intended to decentralize life sciences by expanding participation and collaboration across life sciences through public equity markets and Web3 infrastructure.

During the presentation, Aditxt will discuss the strategic vision behind bitXbio and highlight current projects spanning autoimmunity, cancer, infectious diseases, and women’s health, including the Company’s planned goals and milestones for 2026. The discussion will reflect the Company’s focus on building a diversified ecosystem of real-world health assets, rather than a single-asset biotechnology model.

“The traditional life sciences model leaves many promising innovations undiscovered, delayed, or inaccessible,” said Amro Albanna, Co-Founder, Chairman, and Chief Executive Officer of Aditxt. “With bitXbio, we are building a platform approach that opens participation, aligns incentives with public health impact, and supports the discovery, development, and deployment of health innovations with the potential to address some of our most pressing health challenges.”

Addressing Global Health Challenges

The bitXbio platform is intended to address a broad range of global health challenges through a diversified portfolio of projects across areas of significant unmet need. The platform’s current focus areas are autoimmune diseases, cancer, infectious diseases, and women’s health. By advancing multiple projects across health areas, the platform seeks to reduce binary risk while enabling sustained innovation and value creation.

Public Equity Market as a Platform Foundation

A core element of the bitXbio strategy is its foundation within the public equity markets, anchored by Aditxt’s Nasdaq listing. By operating as a publicly traded company, Aditxt aims to provide transparency, regulatory oversight, and long-term alignment among innovators, stakeholders, and investors, while enabling capital formation to support the discovery, development, and commercialization of health innovations over time.

Expanding Participation Through Web3 Infrastructure

Looking ahead, bitXbio envisions incorporating Web3 infrastructure into its ecosystem to further expand participation, transparency, and engagement. These technologies are being explored as tools to support governance, stakeholder involvement, and ecosystem alignment. The Company believes this approach can help create a more inclusive and resilient life sciences platform.

At The MoneyShow, Aditxt will participate in multiple presentations and host an exhibition booth, providing attendees with opportunities to engage directly with members of the Company’s leadership team and learn more about the bitXbio platform and its portfolio of health initiatives.

Presentation Schedule
Tuesday, February 24: Breakout Room, 12:15 PM – 1:00 PM
Tuesday, February 24: Stage Presentation, 4:45 PM – 5:30 PM

Booth
Booth No. 217

About Aditxt, Inc.

Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. The Company currently operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health.

Forward-Looking Statements

This press release includes “forward-looking statements,” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “aim,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “will,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding Aditxt’s strategic vision for bitXbio, the development and advancement of platform projects, the integration of Web3 infrastructure, and anticipated milestones and outcomes. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company’s SEC filings, including Aditxt’s Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent Form 10-Q filings, including the most recent filed on November 18, 2025. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.

Media Contact
Aditxt, Inc.
Investor Relations
IR@aditxt.com